#AAO22 conference in Chicago (Photo credit: Associate editor Kyle LaHucik)

#AAO22: In bid for first FDA nod in ge­o­graph­ic at­ro­phy, Apel­lis claims an­oth­er first in eye dis­ease field

CHICA­GO — Eight weeks be­fore pa­tients and in­dus­try find out if the FDA ap­proves the first treat­ment for ge­o­graph­ic at­ro­phy, an ad­vanced form of age-re­lat­ed mac­u­lar de­gen­er­a­tion, the biotech be­hind the drug is out with some new da­ta on a sec­ondary end­point.

In what study in­ves­ti­ga­tor Charles Wykoff called the “first di­rect ev­i­dence of func­tion preser­va­tion by slow­ing GA growth” in an in­ves­ti­ga­tion­al treat­ment, Apel­lis Phar­ma­ceu­ti­cals’ drug pegc­eta­coplan led to less loss of reti­nal sen­si­tiv­i­ty ver­sus sham  with­in 250 mi­crons on ei­ther side of the GA le­sion over 24 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.